Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature.
Platinum-based chemotherapy is the standard treatment for ovarian cancer, with response rates of 70-80%. Docetaxel has an increasing role as salvage therapy in patients with platinum-refractory ovarian cancer. In this report, we present the case of a patient with platinum-refractory ovarian cancer who achieved a long-term complete remission with docetaxel therapy. Two years after completion of chemotherapy with docetaxel, she continues to have no evidence of disease.
Balat
O
O
University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Kudelka
A P
AP
Edwards
C L
CL
Verschraegen
C F
CF
Kavanagh
J J
JJ
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin